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Introduction
Neuroacanthocytosis is a rare movement disorder 
characterized by progressive muscle weakness and 
atrophy, progressive cognitive loss, chorea, and 
acanthocytosis (1). Acanthocytes, abnormal thorny red 
blood cells (RBC), are one of the biological hallmarks 
of neuroacanthocytosis syndromes (NA) that is a group 
of rare hereditary neurodegenerative disorders (2). 
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Abstract
Neuroacanthocytosis syndromes (NA) include autosomal recessive chorea-acanthocytosis and X-linked McLeod syndrome 
consisting of a choreatic movement disorder, psychiatric manifestations and cognitive decline, and additional multi-system 
features including myopathy and axonal neuropathy. Fluor 18 -2-fluoro-2-deoxyglucose (18F-FDG-PET) positron emission 
tomography (PET) and technetium 99m -d, l-hexamethyl-propylene amine oxime (99mTc-HMPAO) brain single photon emission 
computed tomography (SPECT) have been increasingly used for the detection of neurologic disorders, such as dementia, 
epilepsy, and movement disorders. In this case report, we report two patients with neuroacanthocytosis syndromes with the 
imaging features of brain metabolism by PET and brain perfusion by SPECT. Brain PET and brain SPECT findings of patients 
with neuroacanthocytosis syndromes were also reviewed.
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Özet
Nöroakontozis sendromları (NA) koreik hareket bozukluğu, psikiyatrik bulgular ve kognitif düşüş ve miyopati ve aksonal 
nöropatiyi içine alan ilave çoklu sistem tutulumundan oluşan otozomal resesif kore-akantozis ve X-linked McLeod 
sendromundan oluşur. Fluor 18-2-fluoro-2-deoxyglucose (18F-FDG) pozitron emisyon tomografi (PET) ve technetium 99m -d, 
l-hexamethyl-propylene amine oxime (99mTc-HMPAO) beyin single photon emission computed tomography (SPECT) demans, 
epilepsi ve hareket hastalıkları gibi nörolojik hastalıkların saptanmasında artan şekilde kullanılmaktadır. Bu olgu sunumunda, 
biz beyin metabolizma PET ve beyin perfüzyon SPECT görüntüleme bulguları olan nöroakantozisli iki hastayı rapor ediyoruz. 
Ek olarak nöroakantozis sendromlu hastalardaki beyin PET ve beyin SPECT bulguları gözden geçirildi. 
Anahtar Kelimeler: Kore-akantozis, McLeod sendromu, nöroakantozis, PET, SPECT 
Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemiştir.
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Neuroacanthocytosis syndromes are exceptionally rare 
with an estimated prevalence of less than 1 to 5 per 1 000 
000 inhabitants for each disorder. The core NA syndromes 
include autosomal recessive chorea-acanthocytosis and 
X-linked McLeod syndrome which have a Huntington’s 
disease-like phenotype consisting of a choreatic movement 
disorder, psychiatric manifestations and cognitive decline, 
and additional multi-system features including myopathy 
and axonal neuropathy. Additionally there are several 
genetically defined disorders in which acanthocytosis is 
occasionally seen, such as pantothenate kinase-associated 
neurodegeneration (PKAN) and Huntington disease-like 2 
(HDL2) (2). 
Fluor 18 -2-fluoro-2-deoxyglucose (18F-FDG-PET) positron 
emission tomography (PET) and technetium 99m -d, 
l-hexamethyl-propylene amine oxime (99mTc-HMPAO) brain 
single photon emission computed tomography (SPECT) 
have been increasingly used for the detection of neurologic 
disorders, such as dementia, epilepsy, and movement 
disorders. In this article, we report two patients with 
neuroacanthocytosis syndromes with the imaging features 
of brain metabolism by PET and brain perfusion by SPECT. 
In addition brain PET and brain SPECT findings of patients 
with neuroacanthocytosis syndromes were reviewed. 
Case Reports
Patient 1 
A 29-year-old male patient who had a 2-year history 
of dysarthria, dysphasia, lip biting and chorea of the 
trunk and limbs was previously admitted to psychiatry 
clinics, and was referred to our department for evaluation 
of neurologic pathologies. His gestation, delivery, and 
early developmental milestones were unremarkable. The 
neurological examination revealed a complex hyperkinetic 
disorder including generalized chorea, orofacial 
dyskinesias, dysarthria with slurred speech, dysphonia, 
and minimal dysdiadochokinesia. The gait was bizarre 
due to both choreatic and dystonic components. Further 
neurological, general and psychiatric examinations were 
normal. The patient’s serum creatine kinase (CK) level was 
1585 U/L (Normal range: 20-200 U/L), myoglobulin was 
198.3 ng/ml (Normal range: 0-110 ng/ml), and serum 
coeruloplasmin, copper, serum lipoprotein electrophoresis, 
and vitamin E levels were within normal limits. Peripheral 
blood smear showed 3-5% acanthocytosis. His EEG 
showed right temporal paroxysmal activity, and the 
patient’s needle electromyography and nerve conduction 
velocities were unremarkable. Cardiac examination 
and echocardiography were also normal. The patient’s 
magnetic resonance imaging (MRI) of the brain which 
was performed in 1.5 Tesla MR system with axial T1-
weighted, T2-weighted, axial proton density, axial fluid 
attenuation inversion recovery (FLAIR) and axial and 
coronal gadolinium-enhanced T1-weighted images was 
normal (Figure 1).
On the 18F-FDG-PET images of the patient, no 18F-FDG 
uptake was observed visually in both caudate nuclei. There 
was minimal 18F-FDG uptake in both lentiform nuclei. The 
activity uptake of the left lentiform nucleus was less than 
that of the right side (Figure 2). In the quantitative analysis, 
hypometabolic areas were identified in the left caudate 
nucleus, left lentiform nucleus, right caudate nucleus and 
left lentiform nucleus. The standard deviations from the 
mean of asymptomatic control group of NeuroQ were 
-5.4108, - 3.4497, -3.2298 and -1.6914, respectively (Figure 
3). 
Patient 2
A 35-year-old male patient, whose cousin was suffering 
from similar complaints such as involuntary movements, lip 
biting, feeding difficulties, involuntary vocalizations, and 
left sided choreatic movement with dystonic component 
was admitted to our hospital. His gestation, delivery, and 
early developmental milestones were unremarkable until 
age 30. The neurological examination revealed a complex 
hyperkinetic disorder including left sided chorea, orofacial 
dyskinesias, dysarthria with slurred speech, dysphonia, 
sudden flexion and extension movements of the left arm, 
dysdiadochokinesia, dystonia, and vocalizations with 
different noises such as snoring, snorting, nonsense words, 
and the syllable “hap”. Hyperkinetic movements were 
more prominent on the left part of the body. Reflexes were 
absent and muscle tonus was reduced. Further neurological 
examinations were normal but cardiac examination 
and echocardiography revealed global akinesia and left 
ventricular myocardial bands. Psychiatric examination 
showed cognitive impairment, depression, and self-neglect. 
The patient’s CK level was 502 U/L, serum ceruloplasmin, 
copper, serum lipoprotein electrophoresis, vitamin E levels 
were within normal limits. Peripheral blood smear showed 
Figure 1. Axial fluid attenuation inversion recovery magnetic resonance 
image showing normal brain
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1-3% acanthocytosis. His EEG, needle electromyography 
and nerve conduction velocities were unremarkable. 
The patient’s MRI of the brain which was performed in 
1.5 Tesla MR system with axial T1-weighted, T2-weighted, 
axial proton density, FLAIR and axial and coronal gadolinium-
enhanced T1-weighted images showed irregularity of 
bilateral caudate, putamen and globus pallidus nuclei 
(Figure 4). 99mTc-HMPAO SPECT showed hypoperfusion in 
the right lentiform nucleus (Figure 5). 
Both patients’ genetic consultations were also 
performed but genetic analyses for the definite diagnosis of 
neuroacanthocytosis syndromes could not be performed. 
The patients were put on tetrabenazine treatment with the 
diagnosis of neuroacanthocytosis syndromes and showed 
minimal clinical improvement. 
Literature Review and Discussion




Leod Syndrome+PET”, and “McLeod Syndrome+SPECT” 
were searched in the US National Library of Medicine 
National Institutes of Health-Pubmed. After examining 
the all results, a total of 11 manuscripts were evaluated 
(3,4,5,6,7,8,9,10,11,12,13). Table 1 summarizes the arti-
cles according to the number and diagnosis of cases, tech-
Figure 2. The PET study was performed with the subjects’ eyes open in a 
dimly lit room and with minimal auditory stimulation. Written consent was 
obtained from each subject after detailed explanation of the procedures. 
PET data were acquired using a Philips Gemini TF PET/CT 16-Scanner (Philips 
Medical Systems, Cleveland, Ohio, USA) (18 cm axial field of view; 4.7 mm 
axial resolution) 50 min. after the intravenous injection of 221 MBq of FDG. 
Data were corrected for both scatter and measured attenuation, which was 
determined by using the CT scan for PET/CT scanner. The 18F-FDG-PET trans-
axial images of the patient did not reveal 18F-FDG uptake visually in both 
caudate nuclei. There was minimal 18F-FDG uptake in both lentiform nuclei. 
The activity uptake of the left lentiform nucleus was less than that of the 
right side
Figure 3. Reorientation was applied to 18F-FDG PET brain data. Reoriented 
image was quantified by NeuroQ program (Philips Medical Systems, 
Cleveland, Ohio, USA). Areas of less than 1.65 SD were accepted as 
hypometabolic areas. Because cerebellum, pons, thalamus uptake were 
visually lower than expected, control and patient values were normalized 
to the value among all pixels in sensory-motor regions in each scan in the 
quantitative analysis. In the quantitative analysis, hypometabolic areas were 
identified as the left caudate nucleus (ICN), left lentiform nucleus (ILN), 
right caudate nucleus (rCN) and right lentiform nucleus (rLN). The standard 
deviations from the mean of asymptomatic control group of NeuroQ were 
-5.4108, - 3.4497, -3.2298 and -1.6914, respectively
Figure 4. Axial T2-weighted magnetic resonance image showing irregularity 
of bilateral caudate, putamen and globus pallidus nuclei
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nique used by nuclear medicine clinics, as well as the results 
of PET and/or SPECT scans. 
Regional brain glucose metabolism in 
neuroacanthocytosis was first described by Dubinsky et al. 
(3), and his patients’ MRI were normal similar to one of our 
patients presented herein (case 1). The visual interpretation 
of the cerebral MRI was reported to be normal in a patient 
with McLeod syndrome with cerebral involvement by Jung 
et al. However, visual interpretation of the PET scans, and 
analysis of region-of-interest values that provided z-scores 
of less than 2 were also reported to be normal in their 
patient (12). In case 1, clinical signs and symptoms of 
cerebral involvement were more prominent and 18F-FDG-
PET scan showed no FDG in the caudate nuclei. Therefore, 
utilization of different neuroimaging techniques would 
be helpful to detect disease involvement, especially in 
asymptomatic cases. 
A study by Müller-Vahl et al. evaluated glucose 
metabolism of monozygotic twins with chorea-
acanthocytosis, and global glucose metabolic rates were 
found normal in both twins. However, glucose uptake was 
relatively reduced in the striatum of both patients. The 
clusters of relative decrease in uptake were significantly 
different between twins, and they concluded that this 
result would be attributed to other environmental factors 
rather than genetic factors (9). 
99mTc HMPAO SPECT showed hypoperfusion in 
the right lentiform nucleus in case 2. Bilateral striatal 
hypometabolism in 18F-FDG-PET, and hypoperfusion in 
99mTc HMPAO SPECT was also previously reported in a case 
of chorea-acanthocytosis (10). Müler-Vahl et al. reported 
reduced striatal dopamine transporter binding on the right 
side, in one of the twins by 123I-2-b-carbomethoxy-3-b-(4-
iodophenyl)-tropane (123I-b-CIT) single photon emission 
computed tomography 123IBZM-SPECT (123IBZM-SPECT) 
scans (9). We think these different results can be explained 
by the wide spectrum of neuroacanthocytosis syndromes 
and different techniques used by nuclear medicine clinics. 
Combined positron-emission tomography and MRI 
studies may improve diagnostic accuracy in patients with 
neuroacanthocytosis syndromes. Peppard et al. reported 
two patients with parkinsonism and neuroacanthocytosis 
whose 18F-FDG PET scans showed nigrostriatal deficit. They 
also reported that these two patients responded well to 
dopaminomimetic therapy (4). As neuroacanthocytosis 
syndromes can present with variable symptoms, use of 
different neuroimaging techniques may be helpful in both 
confirming the diagnosis and deciding on symptomatic 
treatment.
Sydenham chorea is one of the most common causes of 
choreatic diseases that shows striatal hypermetabolism on 
PET-CT images (14). In our cases, the ratio of acanthocytosis 
was fewer than 5%, and although they had some clinical 
clues to diagnosis, the differential diagnosis of choreatic 
movement disorders characterized by basal ganglia 
hypermetabolism such as autoimmune causes or Sydenham 
chorea could be achieved by the information gained from 
both PET and SPECT examinations. 
In summary, nuclear medicine techniques used 
for evaluating brain activity in patients with chorea-
neuroacantocytosis syndromes include SPECT studies using 
123I-IMP, 123I-IBZM, 99mTc-ECD HMPAO SPECT, and PET 
studies by 18F-FDG PET and PET with oxygen-15 steady 
state technique. Reduced striatal metabolism is the most 
common finding in 18F-FDG PET studies. In addition, Saiki 
et al. also reported hypometabolism of the frontal cortex 
in patients with chorea-acanthocytosis (7). Reduced striatal 
dopamine D2-receptor binding is the common finding 
in all SPECT studies. When all case reports are assessed 
together; it is difficult to claim existence of a strong 
correlation between clinical signs and PET and/or SPECT 
findings. Further case reports and studies would be helpful 
to understand the clinical utility of PET and/or SPECT in 
patients with neuroacanthocytosis syndromes. 
Figure 5. The patient rested in the supine position, with closed eyes, within 
a silent and darkened room for approximately 20 min. 99mTc- HMPAO 
was prepared according to the manufacturer’s instructions and 550 MBq 
of 99mTc- HMPAO was injected through an IV canula. The SPECT study 
was performed 30 min. after injection. A single-head 360 degree rotating 
CamStar AC/T gamma camera (GE, Milwaukee, Wisc., USA) equipped with 
a LEAP collimator was used for SPECT acquisition. The patient’s head was 
fixed in a plastic head holder apparatus to minimize motion artifacts. Data 
were obtained in 128x128 matrices, 1.6 zoom and at 3 degree intervals 
for 20 sec/frame. Hamming filter (0.7:0.54) was used for reconstruction 
of SPECT data. Attenuation correction was not performed. Trans-axial and 
sagittal images of 99mTc-HMPAO SPECT showed hypoperfusion in the right 
lentiform nucleus
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Table 1. The number and diagnosis of cases, technique used by nuclear medicine clinics, the results of PET and/or 
SPECT scans







Dubinsky et al.; Regional 
brain glucose metabolism in 
neuroacanthocytosis 
2 Neuroacanthocytosis 18F-FDG PET Glucose hypometabolism of the 
caudate and putamen
Peppard et al.; Parkinsonism with 
neuroacanthocytosis
2 Neuroacanthocytosis 18F-FDG PET Nigrostriatal hypometabolism
Selcuk et al.; Reduction of glucose 
metabolism in basal ganglia 
diagnosed with FDG-PET scan: a 
neuroacanthocytosis case
1 Neuroacanthocytosis 18F-FDG PET No metabolism in the bilaterally 
caudate nuclei and putamen.
Delecluse et al.; Frontal 
impairment and hypoperfusion in 
neuroacanthocytosis
1 Neuroacanthocytosis 99mTc HMPAO 
SPECT
Hypoperfusion in both frontal lobes 
and slight flow decrease in the caudate 
nuclei




18F-FDG PET Hypometabolism of the striatum and 
mild hypometabolism of the frontal 
cortex
Tanaka et al.; Cerebral hypoperfusion 
and hypometabolism with altered 
striatal signal intensity in chorea-








Reduced regional cerebral blood flow 
and oxygen metabolism in the caudate 
nuclei and putamen
Müller-Vahl et al.; Chorea-
acanthocytosis in monozygotic 
twins: clinical findings and 
neuropathological changes as 
detected by diffusion tensor imaging, 





PET: Bilaterally reduced glucose 
utilization in the striatum 
SPECT: Reduced striatal dopamine 
transporter binding on the right side in 
twin 1
Bader et al.; Bilateral temporal lobe 







Bilaterally hypometabolism in the 
striatum
Oechsner et al.; Reduction of striatal 
glucose metabolism in McLeod 
choreoacanthocytosis
2 McLeod Syndrome 18F-FDG PET and
123IBZM-SPECT 
PET: Reduced metabolism in the 
striatum which was significant in one of 
the patients
SPECT: Diffuse reduction of dopamine 
D2 binding sites in the region of 
bilateral caudate nuclei and putamen in 
one patient 
Jung et al.; McLeod phenotype 
associated with a XK missense 
mutation without hematologic, 
neuromuscular, or cerebral 
involvement
1 McLeod Syndrome 18F-FDG PET Normal
Danek et al.; Cerebral involvement in 
McLeod syndrome
1 McLeod syndrome 123I-IMP SPECT Reduced striatal dopamine D2-receptor 
binding 
18F-FDG PET: (18F)-2-fluoro-2-deoxyglucose PET scan, 123I-IMP-SPECT: N-isopropyl-4-(123I) iodoamphetamine single photon emission computed tomography, 123IBZM-SPECT: 
123I-2-b-carbomethoxy-3-b-(4-iodophenyl)-tropane (123I-b-CIT) single photon emission computed tomography, 99mTc HMPAO SPECT: Cerebral blood flow tomography, by xenon 
133 inhalation or technetium 99m HMPAO (99mTc-d, l-hexamethyl-propylene amine oxime) injection single photon emission computed tomography
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